Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05524155
Other study ID # SRHCL
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date September 2022
Est. completion date December 2024

Study information

Verified date August 2022
Source Tianjin Medical University Cancer Institute and Hospital
Contact Tongguo Si
Phone 18526812877
Email 18526812877@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Sign written informed consent before performing any trial related procedures - = 18 years old - Histologically or cytologically proven unresectable metastatic colorectal cancer with liver metastases (AJCC 8th IV) - Intolerance to second-line therapy, or disease progression during or after second-line therapy (RECIST V1.1) - At least one radiographically measurable lesion, according to the RECIST V1.1 criteria - Patients with asymptomatic brain metastases or stable symptoms after local treatment were allowed to enroll if they met the following criteria: - Measurable lesions outside the central nervous system - No central nervous system symptoms, or symptoms not worsened for at least 2 weeks - No glucocorticoid therapy was required or glucocorticoid therapy was discontinued within 7 days before the first study drug administration - Palliative radiation therapy (including craniocerebral radiation for symptomatic brain metastases) was permitted, provided that the radiation had ended at least 1 week before enrollment and that the radiotherapy-related toxicity had recovered to grade 1 or less (CTCAE 5.0, except alopecia). - ECOG PS scores 0-1 - The expected survival time was >3 months - Sufficient organ functions, the subjects need to meet the following laboratory indicators: - ANC =1.5×10^9/L without the use of granulocyte colony-stimulating factor in the last 14 days - Platelets =90×10^9/ without blood transfusion in the past 14 days - Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days - Total bilirubin =1.5× upper limit of normal (ULN); Or total bilirubin >ULN but direct bilirubin = ULN - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in =2.5×ULN (ALT or AST =5×ULN allowed in patients with liver metastases) - Serum creatinine = 1.5 × ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) = 60 ml/min - Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) =1.5 × ULN - Normal thyroid function, defined as thyroid stimulating hormone (TSH) within normal limits. If the baseline TSH was outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range could also be enrolled - The myocardial zymogram is within the normal range (if the investigator comprehensively determines that the simple laboratory abnormality is not of clinical significance, it is also allowed to be enrolled) - Pregnancy test negative and use birth control Exclusion Criteria: - Previous treatment with regorafenib - Previous treatment with anti-PD-L1, anti-PD-L2 drugs, or other drugs that stimulates or synergistically inhibits T-cell receptors (e.g., CTLA-4, OX-40, CD137) - Symptomatic or high risk of obstruction, bleeding, perforation, pneumonia (including noncommunicable pneumonia with previous hormonal therapy and pneumonia in patients receiving treatment) - Malignancy other than colorectal cancer diagnosed within 5 years before the first dose (excluding radical basal cell carcinoma of the skin, squamous carcinoma of the skin, and/or carcinoma in situ after radical resection) - currently participating in an interventional clinical study treatment, or has received another study drug or used a study device within 4 weeks prior to the first dose - Systemic systemic therapy with proprietary Chinese medicine or immunomodulatory agents (including thymosin, interferon, and interleukin, except for local use to control pleural effusion) with anti-tumor indications was received within 2 weeks before the first dose - Active autoimmune disease requiring systemic therapy occurred within 2 years before the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy - Receiving systemic glucocorticoid therapy (excluding intranasal, inhaled, or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first dose; Physiological doses of glucocorticoids (=10 mg/day or equivalent prednisone) are permitted - Blood transfusion within 7 days before the first dose - Clinically uncontrollable pleural effusion/abdominal effusion - Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation - Known allergy to the active ingredient or excipient of the study drug - Not fully recovered from toxicity and/or complications caused by any intervention (= grade 1 or baseline, excluding fatigue or alopecia) before starting treatment - HIV 1/2 antibody positive - Untreated active hepatitis B, subjects who met the following criteria could also be enrolled: - HBV viral load <1000 copies/ml (200 IU/ml) before the first dose, subjects should receive anti-HBV therapy to avoid virus reactivation throughout the study - Subjects with anti-HBC (+), HBsAg (-), anti-HBs (-), and HBV viral load (-) did not require prophylactic anti-HBV therapy, but did require close monitoring for viral reactivation - Active HCV-infected - Received live vaccine within 30 days prior to the first dose,Inactivated virus vaccines for injectable use against seasonal influenza are permitted up to 30 days before the first dose,live attenuated influenza vaccines administered intranasally not allowed - Pregnant or lactating woman - With any severe or uncontrolled systemic disease - Other conditions that the subjects are not suitable to participate in this study according to the judgment of the investigator

Study Design


Intervention

Drug:
HAIC
hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Sintilimab
200mg IV d1,Q3W
Regorafenib
80mg/day,PO,QD,d1~21,Q4W

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University Cancer Institute and Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events (AEs) Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0 up to 24 months
Primary Overall response rate ( ORR) Defined as proportion of patients who have a best response of CR or PR up to 24 months
Secondary Disease control rate (DCR) Defined as proportion of patients who have a best response of CR, PR or SD up to 24 months
Secondary Duration of response (DoR) Defined as the time from first confirmed response (CR or PR) to the date of the first documented tumor progression or death due to any cause, whichever occurs first. up to 24 months
Secondary Progression free survival (PFS) Defined as the time from enrollment to disease progression or death, whichever occurs first up to 28 months
Secondary Overall survival (OS) Defined as the time from the date of treatment start to the date of death up to 28 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A